Search academic texts

Information × Registration Number 0219U001329, 0116U000156 , R & D reports Title Clinical and pathogenetic features of the course of malignant and severe resistant hypertension, the development of new and improvement of existing treatment technologies popup.stage_title Head Mishchenko, Registration Date 24-01-2019 Organization NCS The M.D.Strashesko Institute of Academy of Medical Sciences of Ukraine popup.description2 In the work the analysis of clinical characteristics, parameters of the daily rhythm of blood pressure, structural and functional data of target organs and their interrelation with humoral factors in patients with resistance course of arterial hypertension was conducted. It has been established that for patients with resistant arterial hypertension (RAH) it is common activation of renin-angiotensinic and sympato-adrenal systems, systemic inflammation of low gradation, more significant lesions of target organs than in patients with pseudo-resistant course of disease, in particular, development of concentric left ventricular hypertrophy, deterioration of its diastolic function with retained release fraction, hypertensive remodeling of carotid arteries with the development of atherosclerotic plaques, deterioration of renal function, decrease of cognitive function. Defeat of target organs is related to the level of systolic blood pressure both office and middle at different periods of the day, activation of renin–angiotensin system, systemic inflammation, and also among themselves. Differentiated approaches to choosing chronotherapy regimens with the use of four antihypertensive drugs are developed. The predictors of their effectiveness are determined. A method for correcting daily blood pressure in patients with resistance to arterial hypertension (AH) has been developed, including the use of three-component therapy, in particular an angiotensin-converting enzyme inhibitor, a diuretic, and an antagonist of calcium. Monitor the office and daily blood pressure (BP) at the beginning and after 3 months, after treatment, and in the presence of low effectiveness of therapy for arterial hypertension after 3 months of treatment, namely not achieving the target blood pressure levels, use the drug Triplexam, in the evening, in one tablet, in a daily dose of 10 / 2.5 / 10 mg, which is more effective than in the morning in patients with a stable course of arterial hypertension, based on the results of daily blood pressure monitoring. Changing the time of application of drugs and their levels of dosage provides increased efficiency and attachment to antihypertensive therapy in patients with RAH, significantly reduces blood pressure, which makes it easier to treat patients with RAH. Product Description popup.authors Безродний В.Б. Купчинська Міщенко Л.А. popup.nrat_date 2020-04-02 Close